Allergen-specific immunotherapy and COVID-19: What happened?
Allergol Immunopathol (Madr)
; 51(2): 148-150, 2023.
Article
in English
| MEDLINE | ID: covidwho-2259772
ABSTRACT
BACKGROUND:
The COVID-19 infection played a key role in the discontinuation of patient treatment, such as allergen-specific immunotherapy, in chronic diseases.OBJECTIVES:
We conducted a retrospective observational study at Verona University Hospital, Verona, Italy, to assess the level of adherence to sublingual immunotherapy (SLIT) in patients affected by allergic rhinitis and mild asthma. MATERIALS ANDMETHODS:
We compared and analysed data related to first prescription and collection of 5-grass-pollen 300-index of reactivity (IR) SLIT and tablet lyophilisate, containing 75,000 standardized quality tablet units (SQ-T) allergen extract of grass-pollen from Phleum pratense L, for the five-year period 2017-2021.In particular we considered the group of naïve patients from 2017 who completed pre-COVID treatment (2017-2019) and the group of naïve patients from 2019 who completed treatment during the COVID period (2019-2021). The significance test used was Student's t-test, and P Ë 0.05 was considered as statistically significant.RESULTS:
In the three-year period 2017-2019, 264 naïve patients began treatment in 2017, of these 181 continued in 2018, 135 continued in 2019. Instead, for the period 2017-2019, there were 226 naïve patients in 2019; of these 139 continued in 2020, and 102 in 2021.CONCLUSIONS:
COVID-19 did not seem to influence adherence to SLIT, which declined independently even in during the pre-pandemic 3-year period.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Rhinitis, Allergic, Seasonal
/
Sublingual Immunotherapy
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Traditional medicine
Limits:
Humans
Language:
English
Journal:
Allergol Immunopathol (Madr)
Year:
2023
Document Type:
Article
Affiliation country:
Aei.v51i2.796
Similar
MEDLINE
...
LILACS
LIS